首页> 美国卫生研究院文献>International Journal of Hypertension >S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine
【2h】

S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine

机译:S-氨氯地平:具有差异的异构体—从消旋氨氯地平转变的时间

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review.
机译:钙通道阻滞剂是用于治疗高血压(HTN)的一线药物。氨氯地平的S-对映体S-氨氯地平(S-AM)在印度和其他国家(如中国,韩国,俄罗斯,乌克兰和尼泊尔)有售。经过近二十年的临床研究,我们对S-AM进行了深入审查。这篇综述讨论了总共42项研究(26项随机对照试验,14项观察性研究和2项荟萃分析)的临床证据,这些证据证实了7400例接受S-AM治疗的患者。与消旋氨氯地平相比,单药治疗以及与其他降压药联合使用时,S-AM在HTN中的疗效和安全性,心绞痛的疗效以及S-AM的多效性均在本文中进行了讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号